#1 Clinical Trials Search in Europe

Bezafibrate

Bezafibrate, a medication primarily used to treat high cholesterol and triglyceride levels, has been the subject of several clinical trials exploring its potential benefits in various medical conditions. These trials aim to investigate the drug’s efficacy and safety in treating disorders such as mitochondrial diseases, bipolar depression, and liver conditions like primary biliary cholangitis. This article summarizes the key findings from recent clinical trials involving bezafibrate and its potential applications beyond its traditional use.

Table of Contents

What is Bezafibrate?

Bezafibrate is a medication that belongs to a class of drugs called fibrates. It is also known by the brand name Bezalip[1]. Bezafibrate is primarily used to treat high levels of fats (lipids) in the blood, particularly triglycerides and cholesterol[2].

What Conditions Does Bezafibrate Treat?

Bezafibrate is used to treat several conditions related to abnormal lipid levels in the blood:

  • Mixed Dyslipidemia: This is a condition where both cholesterol and triglyceride levels in the blood are elevated[1].
  • Primary Biliary Cholangitis (PBC): A chronic liver disease where bezafibrate may help improve liver function and reduce symptoms like itching[3].
  • Mitochondrial Diseases: Some studies are investigating bezafibrate’s potential in treating certain rare genetic disorders that affect cellular energy production[4].
  • Fatty Acid Oxidation Disorders: Research is ongoing to determine if bezafibrate can help in conditions where the body has difficulty breaking down certain fats[5].

How Does Bezafibrate Work?

Bezafibrate works by activating special proteins in the body called peroxisome proliferator-activated receptors (PPARs). These proteins help regulate how the body processes fats and sugars. By activating PPARs, bezafibrate can[2][4]:

  • Lower triglyceride levels in the blood
  • Increase levels of “good” cholesterol (HDL)
  • Improve the body’s ability to break down and use fats for energy
  • Potentially enhance the function of mitochondria, the “powerhouses” of cells

Dosage and Administration

The typical dosage of bezafibrate varies depending on the condition being treated:

  • For lipid disorders: 400 mg once daily or 200 mg three times daily[1]
  • For research in mitochondrial diseases: 400 mg daily, sometimes increased to 600 mg daily[4]
  • For primary biliary cholangitis studies: 400 mg daily[3]

Always take bezafibrate exactly as prescribed by your doctor. The medication is usually taken orally, with or after meals.

Potential Side Effects

Like all medications, bezafibrate can cause side effects, although not everyone experiences them. Common side effects may include[3]:

  • Digestive issues (nausea, stomach pain, diarrhea)
  • Headache
  • Dizziness
  • Muscle pain or weakness

Rare but serious side effects can include liver problems or severe muscle damage (rhabdomyolysis). It’s important to inform your doctor immediately if you experience unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or general ill feeling[3].

Ongoing Research and Potential New Uses

Researchers are exploring bezafibrate’s potential in treating several other conditions:

  • Mitochondrial Myopathy: Studies are investigating whether bezafibrate can improve energy production in the muscles of people with certain mitochondrial disorders[4].
  • X-linked Adrenoleukodystrophy (X-ALD): This rare genetic disorder affects the nervous system. Research is examining if bezafibrate can help reduce the buildup of very long chain fatty acids associated with this condition[6].
  • Bipolar Depression: A small study is looking at whether bezafibrate might have antidepressant effects in people with bipolar disorder[7].
  • Fatty Acid Oxidation Disorders: These are rare genetic conditions where the body can’t properly break down certain fats. Scientists are studying if bezafibrate can help improve fat metabolism in these disorders[5].

It’s important to note that these are areas of ongoing research, and bezafibrate is not yet approved for treating these conditions. Always consult with your healthcare provider about the most appropriate treatments for your specific situation.

Condition Study Design Duration Primary Outcome Key Findings
Mixed Dyslipidemia Randomized, double-blind 90 days Change in triglycerides, total cholesterol, LDL-c, HDL-c, VLDL Pending results
Mitochondrial Myopathy Open-label pilot study 12 weeks Change in respiratory chain enzyme activity Pending results
Acute Myocardial Infarction Randomized, controlled 1 month Fibrinogen levels, inflammatory response Pending results
X-linked Adrenoleukodystrophy Open-label pilot study 24 weeks VLCFA levels in plasma, lymphocytes, and erythrocytes Pending results
Bipolar Depression Open pilot trial 8 weeks Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Pending results
Primary Biliary Cholangitis Randomized, double-blind, placebo-controlled 24 months Percentage of patients with complete biochemical response Pending results

FAQ

  • What is bezafibrate and how does it work? Bezafibrate is a medication that belongs to the fibrate class of drugs. It works by activating peroxisome proliferator-activated receptors (PPARs), which help regulate lipid and glucose metabolism in the body. This action can lead to reduced levels of triglycerides and increased levels of 'good' HDL cholesterol.
  • What conditions are being studied in clinical trials using bezafibrate? Clinical trials are exploring the use of bezafibrate in various conditions, including mitochondrial diseases, X-linked adrenoleukodystrophy, bipolar depression, primary biliary cholangitis, and type 2 diabetes. These studies aim to investigate the drug's potential benefits beyond its traditional use in treating high cholesterol and triglycerides.
  • Is bezafibrate being studied for any rare diseases? Yes, bezafibrate is being studied for rare diseases such as X-linked adrenoleukodystrophy (X-ALD) and mitochondrial myopathy. In these trials, researchers are investigating whether bezafibrate can help reduce very long chain fatty acid (VLCFA) levels in X-ALD patients and improve cellular energy production in mitochondrial diseases.
  • What are some potential side effects of bezafibrate? Common side effects of bezafibrate may include gastrointestinal issues like nausea and abdominal pain, muscle problems, and changes in liver function tests. In clinical trials, researchers closely monitor patients for these and other potential adverse effects to ensure the drug's safety.
  • How long do typical clinical trials with bezafibrate last? The duration of clinical trials involving bezafibrate varies depending on the condition being studied and the trial's objectives. In the trials mentioned, durations ranged from 8 weeks to 24 months. For example, the bipolar depression study lasted 8 weeks, while the primary biliary cholangitis trial continued for 24 months.

Ongoing Clinical Trials on Bezafibrate

  • Study on Bezafibrate for Patients with Primary Biliary Cholangitis Not Responding Well to Ursodeoxycholic Acid

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Long-Term Safety of Obeticholic Acid and Bezafibrate for Patients with Primary Biliary Cholangitis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Croatia Czechia Estonia France Germany +6

  • Study on the Effects of Bezafibrate and Obeticholic Acid for Patients with Primary Biliary Cholangitis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Bezafibrate for Patients with Primary Sclerosing Cholangitis and Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy

    Not recruiting

    1 1 1
    Investigated drugs:
    France

  • Study on the Effects of Obeticholic Acid and Bezafibrate for Patients with Primary Biliary Cholangitis Who Cannot Tolerate Ursodeoxycholic Acid

    Not recruiting

    1 1
    Investigated drugs:
    Belgium Croatia Czechia Estonia France Germany +6

Glossary

  • Bezafibrate: A medication belonging to the fibrate class of drugs, used primarily to treat high cholesterol and triglyceride levels. It works by activating peroxisome proliferator-activated receptors (PPARs).
  • Mitochondrial diseases: A group of rare inherited disorders that affect the mitochondria, which are the energy-producing structures in cells. These diseases can cause a wide range of symptoms, often affecting organs with high energy requirements.
  • X-linked adrenoleukodystrophy (X-ALD): A rare genetic disorder characterized by the buildup of very long chain fatty acids (VLCFAs) in the body, which can lead to nervous system damage and adrenal gland dysfunction.
  • Primary biliary cholangitis (PBC): A chronic liver disease that slowly destroys the bile ducts in the liver, potentially leading to liver damage and cirrhosis.
  • Ursodeoxycholic acid (UDCA): A medication used to treat primary biliary cholangitis and other liver conditions. It helps improve bile flow and reduce liver damage.
  • Fibrates: A class of medications used to treat high cholesterol and triglyceride levels. They work by activating peroxisome proliferator-activated receptors (PPARs).
  • Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors that play important roles in regulating metabolism, particularly in lipid and glucose homeostasis.
  • Very long chain fatty acids (VLCFAs): Fatty acids with 22 or more carbon atoms, which can accumulate in certain genetic disorders like X-linked adrenoleukodystrophy.
  • Bipolar depression: The depressive phase of bipolar disorder, characterized by low mood, decreased energy, and other depressive symptoms.
  • Cholestatic itch: Itching associated with liver diseases that affect bile flow, such as primary biliary cholangitis.

References

  1. https://clinicaltrials.gov/study/NCT02548832
  2. https://clinicaltrials.gov/study/NCT02291796
  3. https://clinicaltrials.gov/study/NCT02701166
  4. https://clinicaltrials.gov/study/NCT02398201
  5. https://clinicaltrials.gov/study/NCT00983788
  6. https://clinicaltrials.gov/study/NCT01165060
  7. https://clinicaltrials.gov/study/NCT02481245